Syed Farhan Zafar

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Andrew H. Ko · 2 shared papers, 2020 · strength 0.18
   • Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
   • Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
2. Fernando Rivera · 2 shared papers, 2020 · strength 0.18
   • Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
   • Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
3. David J. Watkins · 2 shared papers, 2020 · strength 0.18
   • Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
   • Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
4. Uwe Pelzer · 2 shared papers, 2020 · strength 0.18
   • Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
   • Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
5. Hana Algül · 2 shared papers, 2020 · strength 0.18
   • Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
   • Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
6. Johanna C. Bendell · 2 shared papers, 2020 · strength 0.18
   • Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
   • Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
7. Madappa N. Kundranda · 2 shared papers, 2020 · strength 0.18
   • Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
   • Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
8. J. Marc Pipas · 2 shared papers, 2020 · strength 0.18
   • Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
   • Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
9. Bassel F. El‐Rayes · 2 shared papers, 2012–2014 · strength 0.14
   • Paper Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma. DOI 10.1097/coc.0b013e318248d8bb↗
   • Paper Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. DOI 10.1517/14728222.2012.691473↗
10. Ganji Purnachandra Nagaraju · 1 shared paper, 2012 · strength 0.05
    • Paper Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. DOI 10.1517/14728222.2012.691473↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.